THE TAPE
NTRA · Medical Laboratories · $41.6B

Natera, Inc. Common Stock

$288.48▼ −9.59%
Last close
Relative strength
83RS
of 99, against every stock▼ -14 on the month
Cooling off
Strong industry, weak stock
−5.7%
six months against Medical Laboratories
52-week range
−34.0%
from the high
$181.00$437.41
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth REALProof PENDING
Quarter to Sep 30, revenue +34% on a year ago
Why it is on no screen

NTRA is off the screens on one check: close to its pivot.

A base has formed6.0 weeks, from 287.83 to 437.41.
Long enough to count6.0 weeks against 3 needed.
Shallow enough34.2% deep against 35% allowed.
Close to its pivot-34.0% from the pivot; listed down to -20%.
Relative strengthRS 83 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
$281.73
-2.3% · tested 4× · last 81 sessions ago
Resistance above
$311.41
+7.9% · tested 4× · last 6 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

Natera, Inc. Common Stock is not on any of the screens right now. Its relative strength rating is 83, and it sits in Medical Laboratories.

Against its industry
Strong industry, weak stockBehind its industry over one and six months while the industry is fully aligned and ahead of the S&P 500.
One month against its industry
-28.4%
Three months against its industry
-17.9%
Six months against its industry
-5.7%

Read against an equal-weighted index of Medical Laboratories, which is +58.5% against the S&P 500 over six months Fully aligned.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 8.5% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$2.9B
+34.1% year on year
Operating margin
-9.0%
Net margin
-5.7%
Free cash flow
$52.5M
0.1% of market cap
Price to sales
14.3×
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 5
Key takeaway
Growth with the cash to show for it: the quarter confirms the thesis.
Revenue
$794.0M
+5.5% QoQ · +34.1% YoY
Gross margin
—
Net income
−$59.9M
Loss
Free cash flow
$5.3M
Cash generating

What the numbers say

  • Good: Revenue +34.1% year over year, +5.5% on the quarter
  • Weak: Net loss $60M, narrower than $67M last quarter
  • Good: Cash generating: operating cash flow $44M, free cash flow $5M
  • Weak: Share count +5.0% in a year: dilution
  • Good: Net cash $1.02B · cash $1.10B
Revenue by quarter
Free cash flow
Net income
shares +5.0% in a year · net cash $1.0B

What is not obvious

  • Weak: Stock compensation $106M added back, 242% of operating cash flow; -$62M after it
  • Weak: Interest $903K a quarter against an operating loss: the debt is carried by the balance sheet, not operations

The desk’s own read

Flagged as drifting down since the report

Final read
Growth: REAL · Economic proof: PENDING
Key question: Can the growth turn into durable profit and cash after its costs and financing?
The next test is operating profit: net loss $60M, narrower than $67M last quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 8 of 46 tracked funds at the end of Q3 2026.

Last quarter: 3 bought new, 4 added, 1 trimmed.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
GappedTape · 2026-11-07
-14.6%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ down on earningsTape · 2026-11-07
-14.6% on earnings 2026-11-05
No measurable effect: stocks behave like random ones over the next three sessions (665 cases over 44 nights).
Unusual volumeTape · 2026-11-07
5.4 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
Reported resultsFiling · 2026-11-06
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Closed below its 20- and 50-day on heavy volumeTape · 2026-11-06
below 20d & 50d on 1.8x volume at 363.76
No measurable effect: stocks behave like random ones over the next three sessions (1,780 cases over 60 nights).
GappedTape · 2026-11-06
-7.0%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ down on earningsTape · 2026-11-06
-7.0% on earnings 2026-11-04
No measurable effect: stocks behave like random ones over the next three sessions (665 cases over 44 nights).
Earnings comingEvent · 2026-11-04
reports 2026-11-05 amc
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
281
$188,620,660 total

Sold: Brophy Michael Burkes, Sheena Jonathan, Rabinowitz Matthew, RABINOWITZ DANIEL, Moshkevich Solomon, Fesko John, Chapman Steven Leonard, Chapman Rowan E, ROSENMAN HERM, Marcus Gail Boxer, BOTHA ROELOF.

Not counted above: 20 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-11-03 Brophy Michael Burkes · CHIEF FINANCIAL OFFICERsell470$184,000
2026-11-02 Sheena Jonathan · Directorsell3$1,165
2026-11-02 Sheena Jonathan · Directorsell109$43,632
2026-11-02 Rabinowitz Matthew · EXECUTIVE CHAIRMAN, Directorsell17$6,599
2026-11-02 Rabinowitz Matthew · EXECUTIVE CHAIRMAN, Directorsell731$292,615
2026-11-02 RABINOWITZ DANIEL · SEC. AND CHIEF LEGAL OFFICERsell7$2,717
2026-11-02 RABINOWITZ DANIEL · SEC. AND CHIEF LEGAL OFFICERsell334$133,698
2026-11-02 Moshkevich Solomon · PRESIDENT, CLINICALDIAGNOSTICSsell9$3,494

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What analysts expect
Strong buy4
Buy16
Hold2
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Natera, Inc. Common Stock (NTRA) — The Tape